TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease

Nature Communications

Volumn 5, Issue , 2014, Pages

  Liu, Yang Lin ^a   Reeves, Helen L ^a   Burt, Alastair D ^a,h   Tiniakos, Dina ^a   McPherson, Stuart ^a   Leathart, Julian B S ^a   Allison, Michael E D ^b   Alexander, Graeme J ^b   Piguet, Anne Christine ^c   Anty, Rodolphe ^a,d   Donaldson, Peter ^a   Aithal, Guruprasad P ^e   Francque, Sven ^f   Van Gaal, Luc ^f   Clement, Karine ^g   Ratziu, Vlad ^g   Dufour, Jean Francois ^c   Day, Christopher P ^a   Daly, Ann K ^a   Anstee, Quentin M ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

^c UNIVERSITY OF BERN   (Switzerland)

^d INSERM   (France)

^e NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^f ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^g PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^h UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTAMIC ACID; LYSINE; PROTEIN; PROTEIN TM6SF2; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; LECTIN; MEMBRANE PROTEIN; NCAN PROTEIN, HUMAN; NERVE PROTEIN; PROTEOCHONDROITIN SULFATE; TM6SF2 PROTEIN, HUMAN;

ALLELE; DISEASE INCIDENCE; GENETIC VARIATION; HISTOLOGY; METABOLISM; POLYMORPHISM;

ADULT; AGE DISTRIBUTION; ARTICLE; BODY MASS; CAUCASIAN; CHROMOSOME 19; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; ENVIRONMENTAL FACTOR; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HISTOLOGY; HOMOZYGOTE; HUMAN; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; PHENOTYPE; AGED; ALLELE; COHORT ANALYSIS; GENETIC PREDISPOSITION; GENETICS; HETEROZYGOTE; LIVER; METABOLISM; MIDDLE AGED; PATHOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; ALLELES; CHONDROITIN SULFATE PROTEOGLYCANS; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HETEROZYGOTE; HUMANS; LECTINS, C-TYPE; LIVER; LIVER CIRRHOSIS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NERVE TISSUE PROTEINS; NON-ALCOHOLIC FATTY LIVER DISEASE; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84903708160     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms5309     Document Type: Article

References (40)

1. Anstee, Q. M., Targher, G. & Day, C. P. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat. Rev. Gastroenterol. Hepatol. 10, 330-344 (2013).
2. Musso, G., Gambino, R., Cassader, M. & Pagano, G. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann. Med. 43, 617-649 (2011).
3. Ekstedt, M. et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 44, 865-873 (2006). (Pubitemid 46489550)
4. Loomba, R. & Sanyal, A. J. The global NAFLD epidemic. Nat. Rev. Gastroenterol. Hepatol. 10, 686-690 (2013).
5. Hirschhorn, J. N. & Gajdos, Z. K. Genome-wide association studies: results from the first few years and potential implications for clinical medicine. Annu. Rev. Med. 62, 11-24 (2011).
6. Altshuler, D., Daly, M. J. & Lander, E. S. Genetic mapping in human disease. Science 322, 881-888 (2008).
7. Anstee, Q. M. & Day, C. P. The genetics of NAFLD. Nat. Rev. Gastroenterol. Hepatol. 10, 645-655 (2013).
8. Romeo, S. et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat. Genet. 40, 1461-1465 (2008).
9. Speliotes, E. K. et al. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet. 7, e1001324 (2011).
10. Chambers, J. C. et al. Genome-wide association study identifies loci influencing concentrations of liver enzymes in plasma. Nat. Genet. 43, 1131-1138 (2011).
11. Al-Serri, A. et al. The SOD2 C47T polymorphism influences NAFLD fibrosis severity: evidence from case-control and intra-familial allele association studies. J. Hepatol. 56, 448-454 (2012).
12. Valenti, L. et al. Homozygosity for the patatin-like phospholipase-3/ adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 51, 1209-1217 (2010).
13. Tan, H. L. et al. Association of glucokinase regulatory gene polymorphisms with risk and severity of non-alcoholic fatty liver disease: an interaction study with adiponutrin gene. J. Gastroenterol. 49, 1056-1064 (2013).
14. Dongiovanni, P. et al. Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease. Gut 59, 267-273 (2010).
15. Aravinthan, A. et al. Gene polymorphisms of cellular senescence marker p21 and disease progression in non-alcohol-related fatty liver disease. Cell Cycle 13, 1489-1494 (2014).
16. Kawaguchi, T. et al. Genetic polymorphisms of the human PNPLA3 gene are strongly associated with severity of non-alcoholic fatty liver disease in Japanese. PLoS ONE 7, e38322 (2012).
17. Trepo, E. et al. Association between the PNPLA3 (rs738409 C4G) variant and hepatocellular carcinoma: evidence from a meta-analysis of individual participant data. Hepatology 59, 2170-2177 (2013).
18. Liu, Y. L. et al. Carriage of the PNPLA3 rs738409 C4G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma. J. Hepatol. 61, 75-81 (2014).
19. Kozlitina, J. et al. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nat. Genet. 46, 352-356 (2014).
20. Holmen, O. L. et al. Systematic evaluation of coding variation identifies a candidate causal variant in TM6SF2 influencing total cholesterol and myocardial infarction risk. Nat. Genet. 46, 345-351 (2014).
21. Gorden, A. et al. Genetic variation at NCAN locus is associated with inflammation and fibrosis in non-alcoholic fatty liver disease in morbid obesity. Hum. Hered. 75, 34-43 (2013).
22. Dyson, J. et al. Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team. J. Hepatol. 60, 110-117 (2014).
23. European Association For The Study Of The Liver; European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J. Hepatol. 56, 908-943 (2012).
24. Kathiresan, S. et al. Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat. Genet. 40, 189-197 (2008). (Pubitemid 351171402)
25. Teslovich, T. M. et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature 466, 707-713 (2010).
26. Anstee, Q. M., McPherson, S. & Day, C. P. How big a problem is non-alcoholic fatty liver disease? BMJ 343, d3897 (2011).
27. McPherson, S. et al. Magnetic resonance imaging and spectroscopy accurately estimate the severity of steatosis provided the stage of fibrosis is considered. J. Hepatol. 51, 389-397 (2009).
28. Bedossa, P. et al. Utility and appropriateness of the FLIP algorithm and SAF score in the evaluation of biopsies of nonalcoholic fatty liver disease. Hepatology. doi:10.1002/hep.27173 (2014).
29. Anstee, Q. M. et al. A candidate-gene approach to validation of genetic modifier associations using a large cohort with histologically characterised non-alcoholic fatty liver disease. J. Hepatol. 58, S46-S46 (2013).
30. Petta, S. et al. Glucokinase regulatory protein gene polymorphism affects liver fibrosis in non-alcoholic fatty liver disease. PLoS ONE 9, e87523 (2014).
31. Valenti, L. et al. I148M patatin-like phospholipase domain-containing 3 gene variant and severity of pediatric nonalcoholic fatty liver disease. Hepatology 52, 1274-1280 (2010).
32. Purcell, S., Cherny, S. S. & Sham, P. C. Genetic Power Calculator: design of linkage and association genetic mapping studies of complex traits. Bioinformatics 19, 149-150 (2003). (Pubitemid 36150192)
33. Carim-Todd, L., Escarceller, M., Estivill, X. & Sumoy, L. Cloning of the novel gene TM6SF1 reveals conservation of clusters of paralogous genes between human chromosomes 15q24-4q26 and 19p13.3-4p12. Cytogenet. Cell Genet. 90, 255-260 (2000). (Pubitemid 32008775)
34. Yamaguchi, K. et al. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology 45, 1366-1374 (2007). (Pubitemid 46918320)
35. Tomita, K. et al. Free cholesterol accumulation in hepatic stellate cells: mechanism of liver fibrosis aggravation in nonalcoholic steatohepatitis in mice. Hepatology 59, 154-169 (2014).
36. Velaga, M. R. et al. The codon 620 tryptophan allele of the lymphoid tyrosine phosphatase (LYP) gene is a major determinant of Graves' disease. J. Clin. Endocrinol. Metab. 89, 5862-5865 (2004). (Pubitemid 39518482)
37. Dyson, J. K., McPherson, S. & Anstee, Q. M. Non-alcoholic fatty liver disease: non-invasive investigation and risk stratification. J. Clin. Pathol. 66, 1033-1045 (2013).
38. Edmondson, H. A. & Steiner, P. E. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer 7, 462-503 (1954).
39. Daly, A. K., Steen, V. M., Fairbrother, K. S. & Idle, J. R. CYP2D6 multiallelism. Methods. Enzymol. 272, 199-210 (1996). (Pubitemid 26299883)
40. Purcell, S. et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet. 81, 559-575 (2007). (Pubitemid 47330214)